Summary of COVID-19 ravulizumab studies

1. Annane et al., Intravenous ravulizumab in mechanically ventilated patients hospitalised with severe COVID-19: a phase 3, multicentre, open-label, randomised controlled trial

201 patient ravulizumab ICU RCT: 8% higher mortality (p=0.76).
RCT 201 mechanically ventilated patients with severe COVID-19 showing no significant difference in mortality with ravulizumab. The study was terminated early due to futility.
Mar 2023, The Lancet Respiratory Medicine, https://www.sciencedirect.com/science/article/pii/S2213260023000826, https://c19p.org/annane

2. Hall et al., Efficacy and safety of baricitinib or ravulizumab in adult patients with severe COVID-19 (TACTIC-R): a randomised, parallel-arm, open-label, phase 4 trial

280 patient ravulizumab late treatment RCT: 1% lower mortality (p=0.98), 53% higher progression (p=0.13), 24% higher need for oxygen therapy (p=0.57), and 3% lower hospital discharge (p=0.86).
RCT 417 hospitalized COVID-19 patients in the UK showing no significant difference in a composite primary endpoint (time to death, invasive mechanical ventilation, extracorporeal membrane oxygenation, cardiovascular organ support, or renal failure) with baricitinib or ravulizumab. The trial was stopped early due to futility. There were no significant differences in secondary outcomes including disease severity, days to discharge, mortality, or adverse events.
Dec 2023, The Lancet Respiratory Medicine, https://www.sciencedirect.com/science/article/pii/S2213260023003764, https://c19p.org/hall3